Literature DB >> 9809220

Depression and Alzheimer's disease.

L E Tune1.   

Abstract

Depressive symptoms, due either major depression or clinically significant, subsyndromal depression, occur commonly in the course of Alzheimer's disease. For a variety of clinical and methodological reasons, this remains an area that begs for new investigation. At the very least, these depressive symptoms should be viewed as a cause of significant and treatable "excess disability" (Kramer and Reifler, 1992). Demented patients with clinically significant depression (e.g., depressed mood, significant loss of appetite, insomnia, fatigue, irritability, and agitation) should be considered for a trial of antidepressant therapy, even when they fail to meet full diagnostic criteria for major depression. These symptoms will, in most instances, respond to antidepressant therapy. The "rules" for treatment of depression in dementia are slightly different than for cognitively intact patients: (a) start low, go slower, (b) pay attention to cognitive toxicity of all medication combinations, and (c) depressive symptoms do not persist as long as in cognitively intact patients. Current treatments, especially those SSRI's like fluoxetine and sertraline that have cognitive enhancing effects, should be considered the "first line" antidepressants. We need to emphasize early detection and treatment of depressive symptoms in dementia in all arenas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809220

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  7 in total

1.  A shift in the paradigm of treatment.

Authors:  Edmund G Howe
Journal:  Psychiatry (Edgmont)       Date:  2006-11

Review 2.  The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

Authors:  G MacQueen; L Born; M Steiner
Journal:  CNS Drug Rev       Date:  2001

3.  Posttraumatic stress disorder-like induction elevates β-amyloid levels, which directly activates corticotropin-releasing factor neurons to exacerbate stress responses.

Authors:  Nicholas J Justice; Longwen Huang; Jin-Bin Tian; Allysa Cole; Melissa Pruski; Albert J Hunt; Rene Flores; Michael X Zhu; Benjamin R Arenkiel; Hui Zheng
Journal:  J Neurosci       Date:  2015-02-11       Impact factor: 6.167

Review 4.  How Studies of the Serotonin System in Macaque Models of Menopause Relate to Alzheimer's Disease1.

Authors:  Cynthia L Bethea; Arubala P Reddy; Fernanda Lima Christian
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Bioinformatics identification of modules of transcription factor binding sites in Alzheimer's disease-related genes by in silico promoter analysis and microarrays.

Authors:  Regina Augustin; Stefan F Lichtenthaler; Michael Greeff; Jens Hansen; Wolfgang Wurst; Dietrich Trümbach
Journal:  Int J Alzheimers Dis       Date:  2011-04-26

6.  Depressive symptoms are associated with analgesic use in people with Alzheimer's disease: Kuopio ALSOVA study.

Authors:  Julia Fiona-Maree Gilmartin; Saku Väätäinen; Soili Törmälehto; J Simon Bell; Eija Lönnroos; Lotta Salo; Ilona Hallikainen; Janne Martikainen; Anne M Koivisto
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

7.  Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer's disease.

Authors:  Arubala P Reddy; Xiangling Yin; Neha Sawant; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2021-05-29       Impact factor: 6.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.